Important considerations in developing CAR-T cell therapy for GBM
Reena Thomas, MD, PhD, Stanford University, Stanford, CA, comments on the importance of managing on-target tumor-associated inflammatory neurologic impacts in patients with glioblastoma (GBM). The therapeutic potential of CAR T cell therapy needs to be balanced with the risk of neurologic sequelae, and it is important to understand the methodology of dosing parameters and patient care to mitigate these impacts. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
